Dermalyser

by AI Medical Technology  · Based in Sweden → — Safer skin cancer diagnosis in seconds
Dermatology Family Medicine Oncology

Contact for details
Regulatory Status Disclosed

Overview

Dermalyser is an AI-powered decision support app designed for medical professionals to obtain a second opinion on skin lesions. It is clinically validated for accurate assessments, boasting a 96% accuracy (AUC) in evaluating skin lesions.

The app aims to facilitate faster diagnoses, reduce unnecessary procedures, and provide greater peace of mind in clinical decisions. It functions by analyzing a dermatoscopic image captured with a smartphone, delivering AI-driven decision support in seconds. Dermalyser demonstrates 95% sensitivity and 85% specificity in melanoma detection, along with a 99.5% Negative Predictive Value (NPV) when ruling out malignancy for benign lesions.

Developed in collaboration with dermatologists and primary care physicians, Dermalyser supports a range of medical professionals including Primary Care Physicians, Dermatologists, and General Practitioners. It is designed to be an assistant, not a replacement, ensuring that the final diagnosis always remains with the healthcare professional.

The use of Dermalyser can lead to significant operational benefits, including potential 56% cost savings and a 79% reduction in unnecessary referrals, by enabling more accurate assessments and reducing overtreatment.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered decision support for skin lesions
  • 96% accuracy (AUC) in assessing skin lesions
  • CE-marked medical device (EU MDR 2017/745, Class IIa)
  • 95% sensitivity and 85% specificity in melanoma detection
  • 99.5% Negative Predictive Value (NPV) for benign lesions
  • 5-second analysis time
  • Smartphone-based dermatoscopic image analysis
  • Reduces unnecessary referrals (79% fewer)
  • Potential for 56% cost savings
  • Validated for Fitzpatrick skin types Iu2013IV

Use Cases

  • Providing a second opinion on suspected skin melanomas
  • Supporting primary care physicians and general practitioners in skin cancer diagnosis
  • Assisting dermatologists with rapid, AI-driven analysis
  • Reducing unnecessary referrals to dermatology specialists
  • Improving diagnostic accuracy and confidence at the point of care
  • Streamlining clinical workflow for skin lesion examination

What Physicians Need to Know

Key Capabilities
AI-driven decision support for analyzing dermoscopic images of suspected melanomas, providing rapid analysis (within seconds) via a smartphone app integrated with a compatible dermatoscope.
Clinical Utility
Aids licensed healthcare professionals (GPs, dermatologists) in early melanoma detection, reducing unnecessary referrals and excisions, improving patient flow, and potentially cutting clinical costs by up to 56%. It acts as a decision-support tool, with the final diagnosis remaining with the clinician.
Integration Options
Primarily a smartphone application (iOS compatible) that works with most dermatoscopes. An AI engine, DermAIM, is available via secure APIs for integration into broader healthcare platforms.
Compliance Status
CE-marked under MDR (EU) 2017/745 as a Class IIa medical device software and is GDPR compliant. A US launch is anticipated in 2027, pending FDA 510(k) clearance.
Pricing Model
Requires a license, which clinics can obtain by contacting AI Medical Technology. Specific pricing details are not publicly disclosed.
User Experience
Designed to be intuitive, fast, and user-friendly, involving three simple steps: starting the app, taking a photo with a dermatoscope, and receiving immediate analysis. It offers multilingual support (English and Swedish).
Support Quality
AI Medical Technology provides digital training, manuals, customer support with defined service levels, and onboarding assistance including installation and staff training.
Implementation Complexity
Requires a clinic license, a smartphone with the app, a compatible dermatoscope, and trained healthcare staff. Onboarding support is provided to facilitate smooth integration into clinical practice.
Evidence Base
Clinically validated through prospective multicenter trials (e.g., AI-DSMM study, NCT05172232) published in peer-reviewed journals like the British Journal of Dermatology. It achieved an AUROC of 0.960, with 95.2% sensitivity and 84.5% specificity for melanoma, and 100% sensitivity and 92.6% specificity for invasive melanomas, outperforming expert dermatologists and general practitioners in studies. The AI model was trained on over 100,000 skin lesion images.
Physician Tip

Dermalyser serves as a powerful decision-support tool, particularly valuable in primary care for initial melanoma screening and guiding referral decisions, and for dermatologists seeking a rapid second opinion. Remember, it's an assistant, not a replacement for your clinical judgment; the final diagnosis is always yours. Be mindful of its validated scope: it's intended for suspected melanomas on Fitzpatrick skin types I-IV and has specific contraindications (e.g., not for patients under 18, ulcerated lesions, or lesions outside 2mm-2cm). Leveraging this tool can enhance diagnostic confidence, streamline patient pathways, and contribute to significant cost savings by reducing unnecessary procedures.

Dermalyser primarily integrates as a smartphone application, requiring a compatible dermatoscope to capture images. For healthcare systems looking for deeper integration, the DermAIM AI engine is available via secure APIs, allowing vendors to embed its clinically validated skin lesion risk assessment capabilities directly into their existing platforms.

Details

Category Dermatology AI, Oncology AI
Pricing Contact for details
DeploymentCloud-based
Compliance
BAA Available No AI-estimated
HIPAA Compliant No AI-estimated
FDA Status No AI-estimated
Integrations
EHR Not specified
Specialties Dermatology, Family Medicine, Oncology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Dermalyser

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Dermalyser.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

Dermalyser is a smartphone application that, when used with a compatible dermatoscope, provides AI-driven decision support for evaluating suspected melanomas. Physicians can capture an image of a skin lesion with the app and receive an immediate analysis to aid in their diagnostic process.
Dermalyser is CE-marked as a Class IIa medical device software under MDR (EU) 2017/745, signifying its adherence to European health, safety, and performance standards. The company anticipates FDA 510(k) clearance for the US market by 2027.
Dermalyser is intended for suspected melanomas and should not be used on patients under 18, ulcerated or open lesions, lesions outside the 2mm-2cm size range, or on mucous membranes, under nails, on palms/soles, near eyes, tattooed skin, or previously biopsied lesions. It has been validated for Fitzpatrick skin types I-IV.
Clinical studies indicate Dermalyser achieved an AUROC of 0.960 for melanoma detection, with 95.2% sensitivity and 84.5% specificity, and 100% sensitivity for invasive melanomas. This performance has been shown to surpass expert dermatologists (AUROC 0.85) and general practitioners (AUROC 0.70).
Several AI dermatology tools exist, such as DermaSensor (FDA cleared for three top skin cancers), SkinVision, and VisualDx. Dermalyser differentiates itself as a CE-marked decision support tool specifically for melanoma, demonstrating superior sensitivity and specificity in clinical trials compared to other AI tools and human assessment.
While specific pricing details are not publicly available, Dermalyser is marketed to offer significant cost savings, with studies suggesting up to a 56% reduction in clinical costs. These savings are attributed to improved patient flow, fewer unnecessary referrals, and reduced excisions of benign lesions.
Dermalyser is explicitly designed as a decision-support tool for licensed healthcare professionals and does not replace the expertise of a dermatologist. The final diagnosis and clinical decision-making always remain the responsibility of the physician.

Related Tools

Rash ID
Rash ID
Dermatology AI
Based on the provided official website text, Rash ID (rashid.com) is a domain name that is currently listed for sale on GoDaddy’s aftermarket. The website content does not describe any medical AI tool, its functions, target users, workflow integration, or specific capabilities. Therefore, no information about a medical AI tool named “Rash ID” can be […]
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
aisencia
aisencia GmbH
Clinical Decision Support & Reference
aisencia GmbH utilizes an AI system to detect and classify around 40 different skin disorders, supporting pathologists by reducing workload and speeding up diagnoses.
Autoderm
Autoderm
Clinical Decision Support & Reference
Autoderm is an AI-powered API that provides pre-triage and informational condition suggestions for teledermatology platforms, aiming to improve efficiency and case quality.
Derm.AI
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
Dermatology AI
Derm.AI is an AI-powered mobile app and software designed by Fraunhofer-Gesellschaft to accelerate skin cancer diagnoses.
HistoGPT
AI Agent
Clinical Decision Support & Reference
HistoGPT is an AI tool that automates the generation of high-quality pathology reports from histology images, aiming to transform dermatopathology by enhancing diagnostic accuracy and efficiency.

See all Dermatology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-30 | First Added: 2026-04-30
AI Tool Finder
AI-powered search. Results may not be comprehensive.